GamaSTAN® is indicated for:
Hepatitis A: The prophylactic value of GamaSTAN® S/D is greatest when given before or soon after exposure to hepatitis A. GamaSTAN® S/D is not indicated in persons with clinical manifestations of Hepatitis A or in those exposed more than 2 weeks previously.
Measles (Rubeola): GamaSTAN® S/D should be given to prevent or modify measles in a susceptible person exposed fewer that 6 days previously. A susceptible person is one who has not been vaccinated and has not had measles previously. GamaSTAN® S/D may be especially indicated for susceptible household contacts of measles patients, particularly contacts under 1 year of age, for whom the risk of complications is highest. GamaSTAN® S/D and measles vaccine should not be given at the same time. If a child is older than 12 months and has received GamaSTAN® S/D, he should be given measles vaccine about 3 months later when the measles antibody titer will have disappeared.
If a susceptible child exposed to measles is immunocompromised, GamaSTAN® S/D should be given immediately Children who are immunocompromised should not receive measles vaccine or any other live viral vaccine.
Varicella: Passive immunization against varicella in immunosuppressed patients is best accomplished by use of Varicella Zoster Immune Globulin (Human) [VZIG]. If VZIG is unavailable, GamaSTAN S/D, promptly given, may also modify varicella.
Rubella: The routine use of GamaSTAN® S/D for prophylaxis of rubella in early pregnancy is of dubious value and cannot be justified. Some studies suggest that the use of GamaSTAN® S/D in exposed, susceptible women can lessen the likelihood of infection and fetal damage; therefore, GamaSTAN® S/D may benefit those women who will not consider a therapeutic abortion.
Immunoglobulin Deficiency: In patients with immunoglobulin deficiencies, GamaSTAN® S/D may prevent serious infection. However, GamaSTAN® S/D may not prevent chronic infections of the external secretory tissues such as the respiratory and gastrointestinal tract. Prophylactic therapy, especially against infections due to encapsulated bacteria, is effective in Bruton-type sex-linked, congenital agammaglobulinemia, agammaglobulinemia associated with thymoma, and acquired agammaglobulinemia.
For indications, dosing and other information, please refer to the prescribing information.